Coughlin M, Deslauriers J, Beauliu M, et al.Role of mediastinoscopy and pretreatment stage in patients with primary lung cancer. Ann Thorac Surg. 1985;40:556-560.
2.
Non-Small Cell Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1995;311:899-909.
3.
Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N.Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer: a systematic review. Thorax. 2002;57:20-28.
4.
Khuri FR, Gleason BS, Meyers ML, et al.Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Proc Am Soc Clin Oncol. 2000;19:205a.
5.
Yuen A, Halsey J, Fisher G, et al.Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol. 2001;20:309a.
6.
Kelly K, Mikhaeel N, Dempsey E, et al.A phase I study of exisulind in previously treated patients with lung cancer. Lung Cancer. 2000;29:76.
7.
Hidalgo M, Siu LL, Nemunaitis J, et al.Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
8.
Folkman J.Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1753-1763.
9.
Gibson SB, Oyer R, Spalding AC, et al.Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol. 2000;20:205-212.
10.
PORT Meta-Analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet. 1998;352:257-263.
